Biopharmaceutical

Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the “Company”),  a clinical stage biopharmaceutical…

The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful resultsThese results pave the way for filing an NDA for the use of PAX-101…

Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage…

10 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in theTreatment of Children with Newly Diagnosed Diffuse Midline…

6 July 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Results of Appeal of Delisting Determination Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage…

Chicago, June 23, 2023 (GLOBE NEWSWIRE) -- In the near future, the biological safety cabinet (BSC) industry is expected to witness significant advancements and transformations driven by…

22 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing a…

26 May 2023 Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering               Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ:…

<!-- Name:DistributionId Value:1000821761 --> <!-- Name:NewsArchiveOrgTags Value:Financial#Financial…

<!-- Name:DistributionId Value:1000821353 --> <!-- Name:NewsArchiveOrgTags Value:Financial#Financial…